BARCELONA, Spain, September 25, 2024--(BUSINESS WIRE)--More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in ...

PHOENIX -- Exacerbation-prone asthma patients who had high blood eosinophil counts or elevated fractional exhaled nitric oxide (FeNO) appeared to benefit from lebrikizumab, pooled data from two ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lebrikizumab treatment improved both face and hand ...

In the ADlong Phase 3b study*, 94% of patients achieved meaningful skin improvement (EASI-75) with up to four years of lebrikizumab treatment, reinforcing the sustained response achieved over time in ...

Interleukin-13 inhibition with lebrikizumab-libkz demonstrates efficacy and safety in pediatric patients with moderate to severe atopic dermatitis. Lebrikizumab-libkz significantly improved disease ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new ...

Patients with moderate to severe atopic dermatitis treated with lebrikizumab maintained improvements in skin clearance at 1 year of treatment, according to long-term findings from two phase 3 trials.

Researchers analyzed pooled safety data from 3 clinical trials of lebrikizumab for uncontrolled asthma to determine the drug’s safety profile. Lebrikizumab has a similar safety profile to placebo in ...

Please provide your email address to receive an email when new articles are posted on . Combination lebrikizumab and topical corticosteroids outperformed topical corticosteroids alone in the treatment ...

Efficacy of the investigational drug lebrikizumab is maintained in patients with moderate to severe atopic dermatitis for at least 1 year, according to new results from the phase 3 ADvocate1 and ...